These findings indicate that the TRIM25/BRD7 signaling axis can be used as a potential target to guide the early diagnosis and treatment of breast cancer patients, and provide a promising strategy for overcoming resistance to PTX and improving the prognosis of breast cancer patients. This evidence concerns the gene TRIM25 and breast cancer.